CMS delayed, without explanation, the national Medicare coverage policy for new expensive hospital-administered cancer drugs that was due to be published Friday (May 17). “CMS will not be issuing a final National Coverage Determination on CAR T-cell therapy for cancer today, but a decision is forthcoming.” states an agency press release on the final national coverage determination for chimeric antigen receptor (CAR) T-cell therapy. That single sentence is all CMS released, and an agency spokesperson declined to say why the...